A system includes a charger and a cracker. An antiviral may be delivered through the charger. The cracker may include a first section and a second section to control the flow of the antiviral from the charger. The first section may receive the charger. The first section and the second section may be coupled together by using screw threads on the first and second sections. The cracker is configured to regulate the flow of antiviral into the user. The antiviral within the charger may include oxygen (O2) and nitrous oxide (N2O). Specifically, the antiviral may a mixture including 75% N2O and 25% O2 that inactivates the DNA and/or RNA of viruses, viroids, and germs.

Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and an additive.

The present disclosure is directed to a lysin-AMP polypeptide construct comprising: (a) a first component comprising the polypeptide sequence of: (i) SEQ ID NO: 118 (GN202); or (ii) a polypeptide having lysin activity and having at least 80% sequence identity with the polypeptide sequence of SEQ ID NO: 118 (GN202); or (iii) an active fragment of SEQ ID NO: 118 (GN202); and (b) a second component comprising the polypeptide sequence of at least one antimicrobial peptide (AMP), wherein the at least one AMP comprises SEQ ID NO: 114 (FIRL). Exemplary lysin-AMP polypeptides, such as GN370 (SEQ ID NO: 44) as well as methods of treating bacterial infections using the present lysin-AMP polypeptide constructs are also disclosed.

Disclosed are a use of an interferon in preparing a drug for preventing novel coronavirus SARS-CoV-2 infection or a disease COVID-19 caused by the novel coronavirus infection, and a drug for preventing novel coronavirus infection or preventing a disease COVID-19 caused by the novel coronavirus infection.

Provided are methods of treating pulmonary artery hypertension with a Kv11.1 (ERG or hERG1) channel inhibitor. In certain embodiments, the Kv11.1 channel inhibitor is dofetilide. In certain embodiments, a subject to be treated using a method of the disclosure is not in need of treatment for an irregular heart rhythm, e.g., atrial fibrillation.

A method of treating a human subject which is effected by inhalation of gaseous nitric oxide, the method comprising a first treatment period comprising administering gNO by inhalation over a period of about at least 5 days, wherein the first treatment period is followed by a second treatment period comprising administering gNO by inhalation over a period of at least 3 months. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract.

This disclosure pertains to pharmaceutical compositions of aerosolized compositions containing mitochondria, methods of preparing and using the compositions, and devices for administering the compositions.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AGER gene. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma.

The present invention relates to pharmaceutical compositions for preventing or treating pulmonary metastasis of cancer. More specifically, the present invention relates to compositions that enhance anti-cancer immunity of the lung rather than induce death of advanced cancer, thus being effective in inhibiting, preventing or treating pulmonary metastasis of cancer.

Disclosed herein are compositions for treating a non-eosinophilic inflammation or inflammatory disorder. The compositions comprise a cannabinoid encapsulated in a drug vehicle. The compositions can be aerosolized for delivery into all pulmonary spaces of a subject in need thereof. The compositions can be used to treat pulmonary inflammatory conditions, including severe asthma (SA), non-eosinophilic asthma, and neutrophilic asthma.